<DOC>
	<DOCNO>NCT02805699</DOCNO>
	<brief_summary>The purpose study confirm efficacy safety BaofeiKang Granule treatment Combined Pulmonary Fibrosis Emphysema patient .</brief_summary>
	<brief_title>A Clinical Evaluation Baofeikang Granule Combined Pulmonary Fibrosis Emphysema Treatment</brief_title>
	<detailed_description>A randomized , double blind , placebo control study conduct observe efficacy safety BaoFeiKang Granule treatment patient Combined Pulmonary Fibrosis Emphysema . The Traditional Chinese Medicine（TCM） syndrome intergal , lung function , Chronic Obstructive Pulmonary Disease Assessment Test（CAT）score , acute exacerbation , arterial blood gas analysis , chest High Resolution Computerized Tomography （HRCT）and liver kidney function calculate tested trial . 1 . Randomization All select case divide experimental group control group randomly , section size 6 . STATISTICAL ANALYSIS SYSTEM（SAS）statistical software randomly assign table，and clinical researcher give correspond code number select qualified patients.According code number , patient receive correspond code number box.The person generate preserve table involve clinical trial . 2 . Drug cod According protocol , experimental duration treatment 3 months.The patient accept medication month . 3 . Blind method In course study , researcher subject aware group research object . 4 . Sample size According formula , n= ( Uα+Uβ ) 2*2P ( 1-P ) / ( P1-P0 ) , require sample size group calculated.P1 represent efficiency treatment group , P0 control group , P= ( P1+P0 ) /2 * 100 % ; α＝0.05，β＝0.10，Uα=1.65，Uβ=1.28.According previous research result literature research , P1=70 % , P0=40 % .It calculate n = 47 , consider shed rate 20 % , n =56.So actual group include 60 patient . 5 . Implementation management ( 1 ) training 4 clinical researcher master case collection method evaluation method minimize selection bias ; ( 2 ) experimental drug use batch drug . ( 3 ) collect data combination medication treatment exclude impact interference ; ( 4 ) inform patient get comprehensive evaluation follow-up treatment.Special problem get respiratory department doctor 's consultation , achieve patient cooperation understanding . ( 5 ) List case loss withdrawal , specify detail reason .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Expectorants</mesh_term>
	<mesh_term>Anti-Asthmatic Agents</mesh_term>
	<criteria>1. conform Combined Pulmonary Fibrosis Emphysema Treatment diagnostic criterion ; 2. conform Qi yin deficiency , phlegm blood stasis syndrome diagnosis standard ; 3 . Patients non acute episode ; 4 . Age 4575 ( include 45 75 ) ; 5. sign inform consent . 1 . Combined upper low respiratory infection , pulmonary tuberculosis , lung cancer lung diseases ; 2 . Combined diabetes , cardiovascular , liver , kidney hematopoietic system disease , psychiatric patient ; 3 . Pregnancy lactation patient ; 4 . Allergic subject medicine . Rejection criterion : 1. meet inclusion criterion enter group ; 2. discovery serious physical illness enter group ; 3. follow program medication patient ;</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Clinical Efficacy</keyword>
	<keyword>Baofeikang Granules</keyword>
	<keyword>Combined Pulmonary Fibrosis Emphysema</keyword>
</DOC>